The ventricular ectopic QRS interval (VEQSI): A potential marker for ventricular arrhythmia in ischaemic heart disease by Bastiaenen, R et al.
 1
The ventricular ectopic QRS interval (VEQSI):  
A potential marker for ventricular arrhythmia in ischaemic heart disease 
 
Rachel Bastiaenen PhD1,2, Hanney Gonna MRCP1,2,3, Navin Chandra MD2, 
Ahmed Merghani MRCP2, Oswaldo Valencia MD1,  
A. John Camm MD*1,2 and Mark M. Gallagher MD*1,2. 
 
1Department of Cardiology, St George’s University Hospitals NHS Foundation Trust, 
London, UK 
2Institute of Cardiovascular and Cell Sciences, St George’s University of London, UK 
3National Heart and Lung Institute, Imperial College London, UK 
* The authors indicated contributed equally to the work 
 
Word Count: 4296 
Brief Title: VEQSI and sudden death in ischaemic heart disease 
Funding sources: Supported by an unrestricted educational grant from Boston Scientific 
Disclosures: MMG has received research funding from Boston Scientific and Medtronic.  
 
Corresponding Author 
Dr Mark M. Gallagher, Director of Cardiac Electrophysiology, St George’s Hospital NHS 
Foundation Trust, London SW17 0QT, United Kingdom 
Email mark_m_gallagher@hotmail.com Tel 02087253079 Fax 02087254117 
 2
 
 3
ABSTRACT 
Background 
The ventricular ectopic QRS interval (VEQSI) has been shown to identify structural heart 
disease and predict mortality in an unselected population. In ischaemic heart disease 
(IHD), risk stratification for sudden death is imperfect. We hypothesized that VEQSI 
would identify patients with prior myocardial infarction (MI) compared with healthy 
subjects and distinguish IHD patients who have suffered life threatening events from 
those without prior significant ventricular arrhythmia. 
Methods  
12-lead Holter recordings from 189 patients with previous MI were analysed: 38 with 
prior life threatening events (MI-VT/VF; 66±9years; 92% male); 151 without prior 
significant ventricular arrhythmia (MI-no VT/VF; 64±11years; 74% male). These were 
compared with 60 normal controls (62±7 years; 70% male). All ventricular ectopic beats 
(VEB) were reviewed and VEQSI max was recorded as the duration of the longest VEB.  
Results 
VEQSI max was longer in post-MI patients compared with normal controls (185±26ms vs 
164±16ms; p<0.001) and in MI-VT/VF patients with prior life threatening events 
compared with MI-no VT/VF patients without prior life threatening events (214±20ms vs 
177±22ms; p<0.001). Multivariate analysis established VEQSI max as the strongest 
independent marker for prior serious ventricular arrhythmia. VEQSI max >198ms had 
86% sensitivity, 85% specificity, 62% positive predictive value and 96% negative 
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predictive value for identifying patients with prior life threatening events (Odds Ratio 
37.4; 95% CI 13.0-107.5).  
Conclusions 
VEQSI max >198ms distinguishes post-MI patients with prior life threatening events 
from those without prior significant ventricular arrhythmia. This may be a useful 
additional index for risk stratification in IHD. 
 
 
Keywords 
IHD, ischaemic heart disease; ICD, implantable cardioverter-defibrillator; SCD, sudden 
cardiac death; VEQSI, ventricular ectopic QRS interval; VEB, ventricular ectopic beat 
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CONDENSED ABSTRACT  
We examined the maximal ventricular ectopic QRS interval (VEQSI) duration during 12-
lead Holter monitoring in 60 normal controls and 189 patients with previous myocardial 
infarction (MI): 38 with prior life threatening events (MI-VT/VF); and 151 without prior 
events (MI no-VT/VF). VEQSI max was longer in post-MI patients compared with 
controls and in MI-VT/VF patients compared with MI-no VT/VF patients. Multivariate 
analysis established VEQSI max as the strongest independent marker for prior life 
threatening events. VEQSI max >198ms distinguished MI-VT/VF patients from MI-no 
VT/VF patients with 86% sensitivity and 85% specificity. This may represent an 
additional index for post-MI risk stratification. 
 6
ABBREVIATIONS 
LVEF = left ventricular ejection fraction 
SCD = sudden cardiac death 
ICD = implantable cardioverter-defibrillator 
IHD = ischaemic heart disease 
MI = myocardial infarction 
VEB = ventricular ectopic beat 
VEQSI = ventricular ectopic QRS interval 
MI-VT/VF = prior myocardial infarction and life threatening ventricular arrhythmia 
MI-no VT/VF = prior myocardial infarction and no significant ventricular arrhythmia 
ECG = electrocardiogram 
NSVT = non-sustained ventricular tachycardia 
VF = ventricular fibrillation 
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INTRODUCTION 
In patients with ischaemic heart disease (IHD), reduced left ventricular ejection fraction 
(LVEF) remains the best established predictor of sudden cardiac death (SCD).(1–3) 
However, in primary prevention trials which selected individuals for implantable-
cardioverter defibrillator (ICD) therapy predominantly on the basis of reduced LVEF, 
only one third had appropriate device therapy over the 3-5 year follow-up.(1; 2) This 
raises concern that many patients are exposed to the risk and expense of ICD therapy 
from which they receive no benefit. The converse is of greater concern: as most IHD-
related SCD occurs in patients with LVEF >35%, many who might benefit are denied the 
protection of an ICD if this criterion is used alone.(4) 
 
Of many electrocardiographic indices proposed as markers of risk for SCD, only the 
conducted QRS interval has shown consistent predictive value in survivors of myocardial 
infarction (MI).(1) With an intact conduction system, however, the QRS remains narrow 
even in the presence of ventricular dilatation and impairment. Ventricular ectopic beats 
(VEB) are usually conducted through ventricular myocardium with limited participation 
of specialized conduction tissue and should therefore provide a better index of the state 
of the myocardium and risk of SCD.(5) In an unselected population attending for Holter 
monitoring, we have shown that the ventricular ectopic QRS interval (VEQSI) and 
number of VEB morphologies correlated with the presence of structural heart disease 
and predicted all-cause mortality.(6) Fragmentation of the conducted QRS and paced 
ventricular electrogram fractionation have also been shown to identify patients at risk of 
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SCD.(7; 8) By extrapolation, fragmentation of the QRS complex of VEB may therefore 
also serve as a marker of risk. 
 
We hypothesized that maximal VEQSI duration (VEQSI max), the number of VEB 
morphologies and maximal VEB fragmentation (VEB fragmentation max) would identify 
patients with prior MI compared with healthy subjects. We hypothesized that these VEB 
indices would distinguish IHD patients who have suffered life threatening events from 
those without a history of significant ventricular arrhythmia, independent of LVEF and 
conducted QRS interval. 
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METHODS 
Patient characteristics 
We recruited 189 patients with previous MI, identified from coronary care records and 
the ICD clinic of St George’s Hospital, London. Acute MI was defined as symptoms and 
ECG changes consistent with infarction and elevated cardiac troponin. Inclusion criteria 
were MI at least 3 months before enrolment and cardiac catheterisation followed by 
revascularisation where appropriate. There were 151 patients (64±11 years; 74% male) 
without prior significant ventricular arrhythmia (MI-no VT/VF cohort) and 38 patients 
(66±9 years; 92% male) with secondary prevention ICD implantation for prior life 
threatening ventricular arrhythmia (MI-VT/VF cohort). Qualifying ventricular arrhythmic 
events in the MI-VT/VF cohort had occurred at least 3 months post-MI. Clinical 
assessment comprised documentation of medical history and medications; physical 
examination including blood pressure, pulse, height and weight; and blood sampling for 
renal function, brain natriuretic peptide (BNP) and inflammatory markers (C-reactive 
protein, CRP; and erythrocyte sedimentation rate, ESR).  
 
Patients were compared with 60 normal controls (62±7 years; 70% male). These were 
individuals without known cardiac risk factors, prior history of cardiac disease or family 
history of inherited heart disease. These healthy volunteers had no significant 
abnormality on electrocardiogram (ECG) and transthoracic echocardiography.  
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The study had previously been given ethical approval by the Outer West London ethics 
committee and it complied with the Declaration of Helsinki. 
 
Electrocardiography 
Digital 10-second 12 lead ECGs were acquired using laptop based software (CardiosoftTM 
GE Healthcare, UK) and reviewed at 10mm/mV and 25mm/s. Intervals including PR, RR, 
QRS and QT were recorded in milliseconds. The QT interval was corrected (QTc) using 
Bazett’s formula. Pathological Q waves and QRS fragmentation (fQRS) were considered 
present when observed in ≥2 ECG leads in the same coronary artery territory. A Q wave 
was defined as ≥40ms in duration or >25% of the following R wave in voltage. fQRS 
included various RSR patterns, as previously described.(9) Ventricular paced QRS 
complexes were excluded from Q wave and fQRS analysis. 
 
Holter monitoring 
Holter monitoring was performed for a 24-hour period. Digital 10-electrode 12 channel 
recording devices with a sampling frequency of 1024Hz (CardioMemR CM 3000-12, 
Getemed, Germany) were applied in the Mason-Likar configuration. Analysis was 
performed on a workstation using commercial Holter analysis software (CardiodayR, 
Getemed, Germany).  
 
All recordings were analysed by the same physician, blinded to the clinical diagnosis, 
who performed careful manual over-reading to eliminate artefact and correct the 
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automated identification of VEB and their classification by morphology. 11 traditional 
Holter ECG variables were selected for evaluation: VEB frequency, ventricular couplets, 
episodes of non-sustained ventricular tachycardia (NSVT), maximum heart rate during 
NSVT, minimum, mean and maximum heart rate, time domain indices of heart rate 
variability (HRV) (standard deviation of NN intervals, SDNN; and HRV triangular index), 
and frequency domain indices of HRV (high and low frequency power). NSVT was 
defined as ≥3 consecutive VEB. Frequent VEB were defined as VEB >1/minute.(10) 
Recordings with persistent atrial arrhythmia, persistent pacing, high frequency of 
ectopic beats and/or poor quality were excluded from HRV analysis. 
 
All VEB in each recording were inspected. Differences in VEB morphology were 
identified with reference to bundle branch block pattern, QRS axis and R wave 
progression.(11) The number of different VEB morphologies was counted and recorded. 
VEQSI and VEB fragmentation were measured for each VEB morphology from a single 
representative QRS complex, chosen for the clarity of its onset and termination (figure 
1). Fusion beats, couplets and NSVT were excluded from analysis. VEQSI measurements 
were made using electronic callipers on a simultaneous 12-derivation ECG segment at 
20mm/mV and 100mm/s. We measured from the start of the QRS showing the earliest 
onset to the end of the QRS showing the latest termination. The duration of the 
broadest VEB was considered to be the VEQSI max of that patient.(6) Fragmentation 
measurements were made on a simultaneous 12-derivation ECG segment at 10mm/mV 
and 25mm/s. VEB fragmentation was defined as >2 notches in the R’ or S waves and/or 
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2 notches separated by >40ms.(12) We recorded the total number of fragmented leads 
for each VEB morphology (excluding lead aVR). The VEB with the maximum number of 
fragmented leads was considered to be the VEB fragmentation max for that patient. 
 
Effect of coupling interval on VEQSI 
A subset of 10 Holter recordings with frequent VEB was reviewed in order to determine 
the effect of coupling interval on VEQSI. The predominant VEB morphology in each 
recording was identified and VEQSI was measured for the maximum and minimum 
coupling intervals and four additional coupling intervals within this range.  
 
Echocardiography 
Echocardiography was performed using standard views from the parasternal and apical 
windows to acquire 2D, colour Doppler and colour tissue Doppler (TDI) images (VIVID 7 
with 4S-MHz probe, GE Vingmed Ultrasound, Horten, Norway). Three consecutive 
cardiac cycles were recorded for each view at end expiration. LV end diastolic diameter 
(LVEDD), LV end systolic diameter (LVESD) and LV wall thickness (LVWT) were derived 
from conventional 2D and M-mode images in the parasternal long and short axis views. 
LVEF was calculated by Simpson’s biplane method using apical 4 and 2 chamber views. 
Results were compared with ASE/ESC guidelines to derive normal and abnormal values 
and to quantify the degree of abnormality present.(13)  
 
Follow-up 
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Patients in the MI-VT/VF cohort were followed up for death and/or further life 
threatening events using patient records, ICD records and stored intracardiac 
electrograms. Events were considered life threatening when appropriate shock therapy 
was delivered for ventricular fibrillation (VF) or rapid sustained VT (rate >200 bpm). 
 
Statistical Analysis 
Statistical data analysis was carried out with SPSS 21.0 (SPSS Inc., Chicago, Illinois, USA). 
Univariate analysis of dichotomous, categorical and continuous data was performed to 
determine their influence or relationship with prior ventricular arrhythmia. The 
distribution of continuous variables was assessed for normality using Shapiro-Wilk test. 
Comparison between groups of continuous data was carried out via independent 
samples t-test after controlling for equality of variance using Levene’s statistic, or Mann-
Whitney U test where appropriate. Chi square test or Fisher’s exact test were used for 
categorical data. Several models of multivariate regression analysis were made using all 
available variables and the most significant markers of prior life threatening ventricular 
arrhythmia were established using forward stepwise (Likelihood Ratio) logistic 
regression analysis. The multivariate analysis was validated using a bootstrap method 
with 1000 repeat samples from the dataset. Receiver operator characteristics (ROC) 
curve analysis was used to determine an optimal cut-off value for VEQSI max. 
Correlations between distributions were made using the Spearman method. A two-
tailed p value <0.05 was considered significant.  
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RESULTS 
Comparison of normal controls and patients with prior myocardial infarction 
The VEB indices were all greater in patients with previous MI compared with normal 
controls: VEQSI max (185±26ms vs 164±16ms; p<0.001); number of VEB morphologies 
(3±3 vs 2±2; p<0.001); and VEB fragmentation max (7±5 vs 2±4; p<0.001; table 1). 
 
Patients with prior myocardial infarction: Comparison of those with and those without 
prior life threatening ventricular arrhythmia  
Patient characteristics 
At the time of assessment, timing of the initial MI was more remote for the cohort with 
prior life threatening events (MI-VT/VF) than the cohort without prior significant 
ventricular arrhythmia (MI-no VT/VF). Patients in the MI-VT/VF cohort included more 
men, with a higher New York Heart Association (NHYA) functional class, BNP, urea and 
creatinine levels and more frequent use of antiarrhythmic medications (table 2). 
 
Electrocardiogram and echocardiogram characteristics 
The conducted QRS duration was longer in MI-VT/VF patients than MI-no VT/VF patients 
(112±45 vs 94±14; p<0.001). Other ECG characteristics were similar. LVEF was lower 
(40±17 vs 55±17; p<0.001) and LVEDD was higher (58±1 vs 49±1; p<0.001) in the MI-
VT/VF cohort compared with the MI-no VT/VF cohort (table 2). 
 
Holter characteristics 
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Ventricular ectopic beats were present in 97% of MI-VT/VF patients and 91% of MI-no 
VT/VF patients. The 24-hour VEB count was higher in the MI-VT/VF cohort than the MI-
no VT/VF cohort (244±714 vs 30±315; p<0.001). Ventricular couplets (3±11 vs 0±1; 
p<0.001) and NSVT (34% vs 11%; p=0.001) were more frequent in MI-VT/VF patients 
than MI-no VT/VF patients (table 2). 
 
Maximal ventricular ectopic QS interval (VEQSI max) 
VEQSI max was longer in MI-VT/VF patients compared with MI-no VT/VF patients 
(214±20ms vs 177±22ms; p<0.001; table 2 and figure 2). When patients were 
subdivided according to LVEF (normal/mildly impaired >45%; moderately impaired 35-
45%; severely impaired <35%) and QRS duration (<120ms; ≥120ms), VEQSI max 
remained longer in the MI-VT/VF cohort within all subdivisions of LVEF and conducted 
QRS interval (table 3).  
 
There was no significant change in VEQSI max within the physiological range of coupling 
intervals demonstrated during Holter monitoring (figure 3). In particular VEQSI max did 
not prolong at shorter coupling intervals. 
 
Number of ventricular ectopic beat (VEB) morphologies 
The number of VEB morphologies was greater in MI-VT/VF patients than MI-no VT/VF 
patients (6±4 vs 3±2; p<0.001; table 2). 
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Maximal VEB fragmentation (fragmentation max) 
VEB fragmentation max was greater in MI-VT/VF patients than MI-no VT/VF patients 
(8±3 vs 6±4; p=0.004; table 2). 
 
Markers of prior life threatening events 
Several univariate markers of prior significant ventricular arrhythmia were identified 
including the VEB indices (VEQSI max, number of VEB morphologies, VEB fragmentation 
max), blood markers (BNP, urea, creatinine), conducted QRS duration, Holter variables 
(VEB count, couplet count, presence of complex VEB, NSVT) and echocardiographic 
parameters (LVEDD, LVEF; table 2). After multivariate logistic regression analysis only 
VEQSI max and LVEDD remained independent markers. VEQSI max demonstrated the 
strongest association, with a 1ms increase in VEQSI max increasing the odds of prior life 
threatening events by a factor of 1.06 (95% Confidence Interval (CI) 1.03-1.09; p<0.001; 
table 4). The bootstrap method confirmed that the magnitude of association for VEQSI 
max and LVEDD with prior significant ventricular arrhythmia withstood resampling and 
is unlikely to be incidental. 
 
The probability of prior significant ventricular arrhythmia increased with VEQSI max 
duration. ROC curve analysis was used to determine the optimal VEQSI max cut-off 
value associated with prior life threatening events. VEQSI max >198ms had 86% 
sensitivity, 85% specificity, 62% positive predictive value (PPV) and 96% negative 
predictive value (NPV) for this (Area Under Curve (AUC) 0.90; 95% CI 0.85-0.95; table 5 
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and figure 4) with an OR 37.4; 95% CI 13.0-107.5. VEQSI max was the superior marker 
compared with LVEDD (AUC 0.90; SE 0.028 vs AUC 0.81; SE 0.04 respectively). 
 
Relationship between VEQSI max, the number of VEB morphologies, VEB 
fragmentation max and LV structural changes 
There was moderate correlation between VEQSI max and LVEDD (rs 0.59; p<0.001) and 
VEQSI max and LVEF (rs -0.58 p<0.001). Correlations between number of VEB 
morphologies and LVEDD (rs 0.46; p<0.001), number of VEB morphologies and LVEF (rs -
0.42; p<0.001), VEB fragmentation max and LVEDD (rs 0.38; p<0.001) and VEB 
fragmentation max and LVEF (rs -0.34; p<0.001) were less strong but still significant. 
 
Antiarrhythmic Drug Therapy 
In the MI-VT/VF cohort there were 12 patients receiving long-term amiodarone therapy. 
As amiodarone use can influence conduction properties, additional analysis was 
performed following the exclusion of these patients. VEQSI max remained significantly 
longer in the MI-VT/VF cohort compared with the MI-no VT/VF cohort (210±16ms and 
172±21ms respectively; p<0.001). No patient received any other class III antiarrhythmic 
medication and none received any class I antiarrhythmic. 
 
Follow-up 
During a mean follow-up period of 48±11 months, 10 patients (26%) in the MI-VT/VF 
cohort suffered further VT/VF events requiring defibrillation and 7 patients (18%) died. 
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These patients all had VEQSI max duration >198ms. VEQSI max was longer in MI-VT/VF 
patients that died or had subsequent VT/VF events requiring defibrillation than in the 
MI-VT/VF patients who survived event free (221±19ms and 205±20ms respectively; 
p=0.028).  
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DISCUSSION 
In this study we have shown that VEB indices: VEQSI max, the number of VEB 
morphologies and VEB fragmentation max identified patients with prior MI compared 
with healthy subjects. In IHD patients, these VEB indices distinguished those who had 
suffered life threatening events (MI-VT/VF) from those without a history of significant 
ventricular arrhythmia (MI-no VT/VF). VEQSI max was greater in MI-VT/VF patients 
irrespective of LVEF and conducted QRS interval and it was the strongest independent 
marker for prior life threatening ventricular arrhythmia. 
 
We have previously demonstrated that in unselected patients attending for outpatient 
Holter monitoring, VEQSI max correlated with presence and severity of structural heart 
disease and multiple VEB morphologies predicted all-cause mortality.(6) ECG data 
recorded during cardiac catheterisation has shown that broadly notched VEB ≥160ms 
are a marker of LV dilatation and impairment.(14) Slowed conduction through diseased 
myocardium has been shown to result in longer QRS duration during VT in patients with 
ARVC and data from electrophysiological studies has shown that longer VEB duration is 
associated with myocardial scar.(15–17) Broader VEB have also been associated with 
development of non-ischaemic cardiomyopathy.(18–20) The greater VEQSI max 
demonstrated in our IHD patients with prior life threatening events likely reflects a 
greater amount of underlying scar and slowed conduction. The incidence of Q wave MI 
was also higher in these MI-VT/VF patients compared with MI-no VT/VF patients, albeit 
not significantly. 
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In this study although increased VEQSI max duration correlated with decreased LVEF, it 
was an independent variable that distinguished IHD patients with prior life threatening 
events from those without significant ventricular arrhythmia. Multivariate logistic 
regression analysis showed it to be the most significant and consistent marker for this. 
VEQSI max >198ms had high sensitivity and specificity for the identification of post-MI 
patients with a previous life threatening event. In addition VEQSI max was greater in IHD 
patients with prior significant ventricular arrhythmia who died or suffered a subsequent 
life threatening event compared with those who survived with no further significant 
ventricular arrhythmia during the follow-up period of 48 months. This suggests that 
VEQSI max may offer incremental value for risk stratification in patients following MI.  
 
Fragmentation of the conducted QRS has been shown to correlate with myocardial scar 
and predict risk in ischaemic cardiomyopathy and BrS.(7; 21) In HCM increased 
fractionation of paced RV electrograms has been shown to correlate with the risk of 
VF.(8; 22) In a prospective study paced ventricular electrogram fractionation (PEFA) also 
predicted patients at risk of SCD with greater accuracy than non-invasive 
techniques.(23) We may have therefore expected fragmentation of the VEB to serve as 
a diagnostic and risk stratification tool in cardiomyopathy but in our multivariate 
analysis it did not feature, apparently due to the superior predictive power of VEQSI 
max. 
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Comparison of VEQSI max, the number of VEB morphologies and VEB fragmentation 
max as indices for previous significant ventricular arrhythmia showed that VEQSI max 
was superior. It is also more convenient. Although 12-lead Holter monitoring improves 
the ability to differentiate between VEB morphologies compared to older 3-derivation 
systems, QRS axis is subject to change with posture and the laborious manual over-
reading required to correct for this is likely to also limit clinical applicability. 
Measurement of VEB fragmentation by the methods that we have used is not possible 
using a standard 3 or 5 lead Holter system, but requires a 12 lead system, limiting its 
utility in clinical practice. The automated measurement of VEQSI max is likely to be more 
robust than that of VEB fragmentation or the number of morphologies, and we have 
previously demonstrated that this index can be determined using Holter monitoring 
systems with fewer leads.(6) We therefore consider VEQSI max to be the most useful of 
the three indices. 
 
Randomised clinical trials have established that ICD therapy can improve survival for 
individuals at risk of SCD.(1) It is therefore important to correctly identify at risk 
individuals for treatment. In patients with IHD, reduced LVEF remains the best 
established predictor of SCD but this is imperfect.(1; 2) The majority of SCD occurs in 
those with low, intermediate or no risk factors and in primary prevention trials which 
selected individuals for ICD therapy predominantly on the basis of reduced LVEF, only 
one third had appropriate device therapy over the 3-5 year follow-up.(1; 2; 4)  
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Prospective follow-up data is needed to determine the potential role for combining 
VEQSI max with LVEF and conducted QRS interval in risk analysis algorithms as well as 
the optimal cut-off value for VEQSI max. Our dataset does demonstrate overlap within 
the 180-200ms range between the two groups. From a clinical perspective a cut-off 
value of 198ms appears most useful. This affords high sensitivity whilst maintaining 
good specificity. When selecting patients for prophylactic ICD implantation, high 
sensitivity and identification of true positives, those at highest risk of ventricular 
arrhythmia, would appear to be the more important factor. Longer prospective follow-
up will be important to determine outcomes of patients with VEQSI max >198ms, 
particularly those in the MI-no VT/VF cohort. 
 23
STUDY LIMITATIONS 
Consecutive patients treated for MI at St George’s Hospital and all IHD patients under 
follow-up in the ICD clinic with secondary prevention devices were invited to take part 
in the study. Only one third agreed which introduces a possibility of selection bias. Our 
data showed VEQSI max was a stronger marker for prior life threatening events than 
LVEF but it must be noted that the MI-VT/VF sample size was modest and included few 
patients with low LVEF. In addition all patients were recruited prospectively, but the 
majority of events occurred before recruitment and this is a retrospective study. 
Prospective follow-up data is required to determine the outcome of patients with longer 
VEQSI max without a history of serious arrhythmia at the time of assessment. 
 
CONCLUSION 
The maximal ventricular ectopic QRS interval (VEQSI max) distinguishes ischaemic heart 
disease patients who have suffered life threatening events from those without a history 
of significant ventricular arrhythmia. VEQSI max shows promise as an additional risk 
stratification tool for sudden death to be considered for use in combination with 
existing indices. 
 
CLINICAL COMPETENCIES 
Reduced left ventricular ejection fraction (LVEF) is the best established predictor of 
sudden death in patients with ischaemic heart disease (IHD), but the majority of events 
occur in those with LVEF >35%. In this study, the maximal ventricular ectopic QRS 
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interval (VEQSI max) was the strongest marker of prior life threatening ventricular 
arrhythmia in post-myocardial infarction patients. 
 
TRANSLATIONAL OUTLOOK 
VEQSI max shows promise as an additional risk stratification index in ischaemic heart 
disease. Prospective follow-up data in a larger cohort is required. This will be of 
particular interest in patients with LVEF 35-50%. 
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FIGURE LEGENDS 
Figure 1 
Measurement of the ventricular ectopic QRS interval (VEQSI). Panel A demonstrates a 
ventricular ectopic beat (VEB) from a patient with prior myocardial infarction (MI) and 
no significant ventricular arrhythmia (MI-no VT/VF cohort). VEQSI measures 173ms. 
Panel B demonstrates a VEB from a patient with prior MI and life threatening ventricular 
arrhythmia (MI-VT/VF cohort). VEQSI measures 213ms. In this example the calibration 
has a gain of 10mm/mV and speed of 100mm/s. 
 
Figure 2 
The maximal ventricular ectopic QRS interval (VEQSI max) in patients with prior 
myocardial infarction (MI) and life threatening ventricular arrhythmia (MI-VT/VF cohort) 
and patients with prior MI but no history of significant ventricular arrhythmia (MI-no 
VT/VF cohort). The notches for the box plots do not overlap which can be regarded as 
strong evidence that previous life threatening arrhythmic events are associated with 
significantly longer VEQSI max. 
 
Figure 3 
Variation of the ventricular ectopic QRS interval (VEQSI) with coupling interval in 
ventricular ectopic beats (VEB) with a uniform morphology. There was no significant 
change in VEQSI max within the physiological range of coupling intervals demonstrated 
during Holter monitoring. 
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Figure 4 
Receiver operator characteristics (ROC) curves for the maximal ventricular ectopic QRS 
interval (VEQSI max) duration and left ventricular end diastolic diameter (LVEDD) in the 
differentiation of ischaemic heart disease (IHD) patients with and without a history of 
significant ventricular arrhythmia (MI-VT/VF and MI-no VT/VF cohorts respectively). 
VEQSI max was a superior marker compared with LVEDD (AUC 0.90; SE 0.028 vs AUC 
0.81; SE 0.04 respectively). VEQSI max >198ms had 86% sensitivity and 85% specificity 
for identification of patients with prior myocardial infarction (MI) and life threatening 
ventricular arrhythmia (MI-VT/VF cohort).  
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TABLES 
Table 1 Comparison of ventricular ectopic indices in normal controls and patients with 
prior myocardial infarction. 
 Normal
controls  
(n=60) 
Patients with  
prior MI 
(n=189) 
p-value
Age (years; mean±SD) 62±7 64±11 0.113 
Sex (male; %) 70 78 0.229 
VEB present (%) 83 92 0.081 
VEQSI max (ms; mean±SD) 164±16 185±26 <0.001 
VEB morphologies (n; median±IQ range) 2±2 3±3 <0.001 
VEB fragmentation max (n; median±IQ range) 2±4 7±5 <0.001 
 
 
MI, myocardial infarction; VEB, ventricular ectopic beat; VEQSI, ventricular ectopic QRS 
interval
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Table 2 Patients with prior myocardial infarction. Comparison of clinical characteristics, 
electrocardiographic and echocardiographic data in those with and those without prior 
life threatening ventricular arrhythmia. 
 MI-VT/VF 
(n=38) 
MI-no VT/VF  
(n=151) 
p-value
Age (years; mean±SD) 66±9 64±11 0.274
Sex (male; %) 92 74 0.017
Medications (%) 
• Beta-blocker 
• Calcium channel blocker 
• ACE inhibitor 
• Amiodarone 
• Digoxin 
95 
0 
95 
32 
16 
 
76 
9 
90 
0 
1 
0.009 
0.061 
0.560 
<0.001 
<0.001 
Time from MI to assessment (months; mean±SD) 137±114 18±18 <0.001
Location of infarct segments (%) 
• Anterior 
• Inferior 
• Lateral 
• Posterior 
• Greater than one territory 
50 
21 
3 
0 
26 
 
33 
26 
8 
1 
32 
0.053 
0.543 
0.471 
1.000 
0.466 
NYHA class (median±IQ range) 2±1 1±1 0.01
Pulse (bpm; median±IQ range) 58±17 62±13 0.341
Systolic BP (mmHg; median±IQ range) 130±28 130±29 0.407
Diastolic BP (mmHg; median±IQ range) 80±15 80±16 0.736
BMI (median±IQ range) 28±8 28±5 0.522
Plasma  
• BNP (median±IQ range) 
• Urea (median±IQ range) 
• Creatinine (median±IQ range) 
• CRP (median±IQ range) 
• ESR (median±IQ range) 
982±2073 
7.7±13 
106±74 
11±16 
24±24 
 
278±600 
5.9±3 
83±19 
10±12 
12±22 
<0.001 
0.018 
<0.001 
0.560 
0.157 
Conducted QRS duration  (ms; median±IQ range) 112±45 94±14 <0.001
QTc interval (ms; median±IQ range) 422±47 416±34 0.108
Q waves* (n%) 24 (75) 89 (60) 0.097
QRS fragmentation* (n%) 21 (55) 79 (52) 0.745
Mean HR (bpm; median±IQ range) 64±13 67±15 0.06
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Subjects with VEB present (n%) 37 (97) 137 (91) 0.176
Number of VEB (n; median±IQ range) 244±714 30±315 <0.001
Number of couplet(s) (n%) 3±11 0±1 <0.001
Presence of frequent VEB (n%) 7 (18) 12 (8) 0.055
Presence of complex VEB (n%) 37 (97) 114 (76) 0.003
Presence of NSVT (n%) 13 (34) 17 (11) 0.001
SDNN (median±IQ range) 138±70 135±55 0.757
HRV triangular index (median±IQ range) 28±17 28±11 0.164
HFP (median±IQ range) 1.46E-08±2.19E-08 8.03E-09±3.52E-08 0.447
LFP (median±IQ range) 1.87E-08±4.06E-08 2.74E-08±1.30E-07 0.247
LVEDD (mm; median±IQ range) 58±1 49±1 <0.001
LVEF (%; median±IQ range) 40±17 55±17 <0.001
  
VEB morphologies (n; median±IQ range) 6±4 3±2 <0.001
VEQSI max (ms; mean±SD) 214±20 177±22 <0.001
VEB fragmentation max (n; median±IQ range) 8±3 6±4 0.004
*Data not available for all patients due to ventricular pacing/bundle branch block 
 
MI-VT/VF, patients with prior myocardial infarction and life threatening ventricular 
arrhythmia; MI-no VT/VF, patients with prior myocardial infarction and no significant 
ventricular arrhythmia; ACE, Angiotensin-converting enzyme; NYHA, New York Heart 
Association functional class; BP, blood pressure; BMI, body mass index; BNP, brain 
natriuretic peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HR, 
heart rate; VEB, ventricular ectopic beat; NSVT, non-sustained ventricular tachycardia; 
VEQSI, ventricular ectopic QRS interval; SDNN, standard deviation of NN intervals; HRV, 
heart rate variability; HFP, high frequency power; LFP, low frequency power; LVEDD, left 
ventricular end diastolic diameter; LVEF, left ventricular ejection fraction 
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Table 3 The maximal ventricular ectopic QRS interval (VEQSI max) in patients with and 
without prior life threatening ventricular arrhythmia stratified by left ventricular 
ejection fraction (LVEF) and conducted QRS interval 
 MI-VT/VF 
VEQSI max  
(ms; mean±SD)  
MI-no VT/VF  
VEQSI max  
(ms; mean±SD) 
p-value
LVEF 
• Normal/Mildly impaired (>45%) 
• Moderately impaired (35-45%) 
• Severely impaired (<35%) 
201±23 
216±18 
221±18 
174±21 
185±21 
194±22 
 
<0.001 
<0.001 
0.004 
 
Conducted QRS interval 
• <120ms 
• ≥120ms 
 
206±16 
228±18 
 
176±22 
188±20 
 
<0.001 
<0.001 
 
MI-VT/VF, patients with prior myocardial infarction and life threatening ventricular 
arrhythmia; MI-no VT/VF, patients with prior myocardial infarction and no significant 
ventricular arrhythmia 
 38
Table 4 Markers of prior significant ventricular arrhythmia in patients with ischaemic 
heart disease. The variables that remained significant following multivariate and logistic 
regression analysis are shown in the table. 
 
 Multivariate Analysis Bootstrap 
 B SE Wald p OR 95% CI SE p Bias 95% CI
LVEDD (cm) 0.864 0.673 1.65 0.2 2.37 0.63-8.87 166 0.25 18.2 -2.73-147.6
VEQSI max (ms) 0.105 0.027 14.7 <0.001 1.11 1.05-1.17 12.5 0.001 2.01 0.082-16.91
Constant -18.2 7.08 6.6 0.01   
 Logistic Regression Analysis (final model)
 B SE Wald p OR 95% CI
LVEDD (cm) 0.835 0.400 4.35 0.037 2.31 1.05-5.05
VEQSI max (ms) 0.060 0.014 18.2 <0.001 1.06 1.03-1.09
Constant -17.9 3.26 30.2 0.000000
 
LVEDD, left ventricular end diastolic diameter; VEQSI max, maximal ventricular ectopic 
QRS interval; B, regression coefficient; SE, standard error; OR, odds ratio; CI, confidence 
interval 
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Table 5 The maximal ventricular ectopic QRS interval (VEQSI max) cut-off values for 
identification of life threatening ventricular arrhythmia in patients with ischaemic heart 
disease. 
 VEQSI max 
195ms 
VEQSI max 
198ms 
VEQSI max  
200ms 
AUC 0.82 0.90 0.85 
Sensitivity 0.86 0.86 0.84 
Specificity 0.77 0.85 0.87 
PPV 0.51 0.62 0.63 
NPV 0.95 0.96 0.95 
OR (95% CI) 21.9 (7.86-60.9) 37.4 (13.0-107.5) 34.2 (12.5-93.3) 
Accuracy 0.79 0.86 0.86 
Prevalence 0.21 0.21 0.21 
LR (95% CI) 3.82 (2.73-5.34) 5.92 (3.87-9.06) 6.38 (4.05-10.0) 
 
AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive 
value; OR, odds ratio; CI, confidence interval; LR, likelihood ratio 
 
 
